Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2026-02-25 @ 7:26 PM
Study NCT ID:
NCT02573935
Status:
TERMINATED
Last Update Posted:
2016-09-20
First Post:
2015-10-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Clarithromycin in Multiple Myeloma Induction Therapy
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2019-01-29', 'releaseDate': '2018-08-16'}, {'resetDate': '2019-08-15', 'releaseDate': '2019-07-05'}], 'estimatedResultsFirstSubmitDate': '2018-08-16'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D009101', 'term': 'Multiple Myeloma'}], 'ancestors': [{'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D020141', 'term': 'Hemostatic Disorders'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010265', 'term': 'Paraproteinemias'}, {'id': 'D001796', 'term': 'Blood Protein Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017291', 'term': 'Clarithromycin'}], 'ancestors': [{'id': 'D004917', 'term': 'Erythromycin'}, {'id': 'D018942', 'term': 'Macrolides'}, {'id': 'D061065', 'term': 'Polyketides'}, {'id': 'D007783', 'term': 'Lactones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 58}}, 'statusModule': {'whyStopped': 'Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone)', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2015-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-09', 'completionDateStruct': {'date': '2016-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-09-19', 'studyFirstSubmitDate': '2015-10-08', 'studyFirstSubmitQcDate': '2015-10-09', 'lastUpdatePostDateStruct': {'date': '2016-09-20', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2015-10-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo', 'timeFrame': '10 weeks'}], 'secondaryOutcomes': [{'measure': 'Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo', 'timeFrame': 'Five months'}, {'measure': 'Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively', 'timeFrame': 'Five months'}, {'measure': 'Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo', 'timeFrame': '9 weeks'}, {'measure': 'Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD', 'timeFrame': 'Three months'}, {'measure': 'Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0', 'timeFrame': 'Five months'}, {'measure': 'Quality of life assessed by EORTC QLQ-MY20', 'timeFrame': 'Five months'}, {'measure': 'Quality of life assessed by EORTC QLQ-C30', 'timeFrame': 'Five months'}, {'measure': 'Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0', 'timeFrame': 'Three months'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Multiple Myeloma', 'Clarithromycin', 'Induction Chemotherapy', 'Transplantation, Autologous'], 'conditions': ['Multiple Myeloma']}, 'referencesModule': {'references': [{'pmid': '20645430', 'type': 'BACKGROUND', 'citation': 'Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep;85(9):664-9. doi: 10.1002/ajh.21777.'}, {'pmid': '30230047', 'type': 'DERIVED', 'citation': 'Nielsen LK, Klausen TW, Jarden M, Frederiksen H, Vangsted AJ, Do T, Kristensen IB, Frolund UC, Andersen CL, Abildgaard N, Gregersen H. Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients. Eur J Haematol. 2019 Jan;102(1):70-78. doi: 10.1111/ejh.13175. Epub 2018 Oct 29.'}, {'pmid': '30123673', 'type': 'DERIVED', 'citation': 'Gregersen H, Do T, Kristensen IB, Frolund UC, Andersen NF, Nielsen LK, Andersen CL, Klausen TW, Vangsted AJ, Abildgaard N. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Exp Hematol Oncol. 2018 Aug 13;7:18. doi: 10.1186/s40164-018-0110-0. eCollection 2018.'}]}, 'descriptionModule': {'briefSummary': 'This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.', 'detailedDescription': 'The survival in younger myeloma patients improved in the nineties with the introduction of high-dose melphalan with autologous stem cell support (HDT). However, all patients will eventually experience relapse after HDT and there is a need for improvement of the response after HDT. The choice of induction treatment before HDT affects the outcome after induction therapy as well as the outcome after HDT.\n\nClarithromycin is a macrolide antibiotic frequently utilized in the treatment of respiratory tract infections and is often used in patients with known hypersensitivity to beta-lactam antibiotic. Besides antibiotic activity, clarithromycin may exert immunomodulatory and anti-inflammatory effects. The toxicity profile of clarithromycin is favourable and the cost is very low.\n\nStudies on cell lines have shown that clarithromycin attenuates autophagy in myeloma cells and a recent study has demonstrated that treatment with clarithromycin enhanced bortezomib-induced cytotoxicity in myeloma cells. Phase II studies without control groups have indicated that clarithromycin might enhance the effect of the thalidomide and lenalidomide. A case-matched analysis compared patients at one centre receiving clarithromycin, lenalidomide and dexamethasone with an equal number of patients at another centre receiving lenalidomide and dexamethasone. This study indicated a favourable effect of clarithromycin with a higher frequency of complete response, very-good-partial-response or better response and progression-free survival. However, there is a need for controlled studies to determine whether clarithromycin might enhance the effect of other myeloma agents.\n\nThis randomized placebo-controlled study will include 160 patients with newly diagnosed multiple myeloma eligible for HDT. The study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma, and is conducted by the Danish Myeloma Study Group (DMSG) at seven clinics in Denmark. The first patient was included in May 2015 and enrolment is expected to continue until October 2016. The study ends when the last included patient has been followed for two months after HDT.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Myeloma diagnosis according to IMWG criteria\n* Treatment demanding disease\n* High-dose melphalan with stem cell support scheduled as a part of the treatment\n* Signed informed consent given prior to any study related activities\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* Allogeneic transplantation scheduled as a part of the treatment\n* Myeloma treatment prior to entry in the study, except radiotherapy, bisphosphonates/denosumab or corticosteroids for symptom control\n* Concurrent disease making clarithromycin treatment unsuitable\n* Positive pregnancy test (only applicable for women with childbearing potential)\n* Known or suspected hypersensitivity or intolerance to clarithromycin\n* Prolonged QT corrected (QTc) interval ( \\> 500 msec on screening ECG)\n* Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide, quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other statins\n* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, uncontrolled angina or known cardiac amyloidosis\n* Severe renal dysfunction (estimated creatinine clearance \\<10 mL/min)\n* Serious medical or psychiatric illness which, in the judgment of the investigator, would make the patient inappropriate for entry into the study'}, 'identificationModule': {'nctId': 'NCT02573935', 'acronym': 'CLAIM', 'briefTitle': 'Clarithromycin in Multiple Myeloma Induction Therapy', 'organization': {'class': 'OTHER', 'fullName': 'Aalborg University Hospital'}, 'officialTitle': 'A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma', 'orgStudyIdInfo': {'id': 'DMSG 03/14'}, 'secondaryIdInfos': [{'id': '2014-002187-32', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Clarithromycin', 'description': 'Clarithromycin combined with VCD induction therapy', 'interventionNames': ['Drug: Clarithromycin', 'Drug: VCD induction therapy']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo combined with VCD induction therapy', 'interventionNames': ['Drug: Placebo', 'Drug: VCD induction therapy']}], 'interventions': [{'name': 'Clarithromycin', 'type': 'DRUG', 'description': 'p.o. clarithromycin 500 mg twice daily for 63 days', 'armGroupLabels': ['Clarithromycin']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo tablet twice daily for 63 days', 'armGroupLabels': ['Placebo']}, {'name': 'VCD induction therapy', 'type': 'DRUG', 'description': 'Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)', 'armGroupLabels': ['Clarithromycin', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'Department of Hematology, Aalborg University Hospital', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '8000', 'city': 'Aarhus', 'country': 'Denmark', 'facility': 'Department of Hematology, Aarhus University Hospital', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': '2100', 'city': 'Copenhagen', 'country': 'Denmark', 'facility': 'Department of Hematology, Rigshospitalet', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}, {'zip': '2730', 'city': 'Herlev', 'country': 'Denmark', 'facility': 'Department of Hematology, Herlev Hospital', 'geoPoint': {'lat': 55.72366, 'lon': 12.43998}}, {'zip': '5000', 'city': 'Odense', 'country': 'Denmark', 'facility': 'Department of Hematology, Odense University Hospital', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'zip': '4000', 'city': 'Roskilde', 'country': 'Denmark', 'facility': 'Department of Hematology, Roskilde Hospital', 'geoPoint': {'lat': 55.64152, 'lon': 12.08035}}, {'zip': '7100', 'city': 'Vejle', 'country': 'Denmark', 'facility': 'Department of Hematology, Vejle Hospital', 'geoPoint': {'lat': 55.70927, 'lon': 9.5357}}], 'overallOfficials': [{'name': 'Henrik Gregersen, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Aalborg University Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Henrik Gregersen', 'class': 'OTHER'}, 'collaborators': [{'name': 'Danish Myeloma Study Group', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Consultant', 'investigatorFullName': 'Henrik Gregersen', 'investigatorAffiliation': 'Aalborg University Hospital'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2018-08-16', 'type': 'RELEASE'}, {'date': '2019-01-29', 'type': 'RESET'}, {'date': '2019-07-05', 'type': 'RELEASE'}, {'date': '2019-08-15', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Henrik Gregersen, Consultant, Aalborg University Hospital'}}}}